BioSpace

FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum

From MSCs to iPSCs: building the cell therapy future

Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay

Fibrosis, IPF and the search for better therapies

Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening

Q1 earnings reports from major pharmaceutical companies and emerging biotechs highlight a period of strategic growth and market recalibration. Pfizer’s conservative guidance despite beating consensus estimates reflects a focus on long-term exclusivity, particularly following the patent settlement for Vyndamax, while El...

Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening

What makes life science angel investment work?

Q1 earnings take off, Lilly strikes deals, Regeneron notches historic approval, FDA raises questions

The next era of diabetes management

Trump’s psychedelics push, Lilly’s up to $7B CAR T deal, Replimune’s saga and Denali’s big win

Funding the Future of European Biotech

J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer

Bonus: Q1 2026 Job Market Update

Automation, Collaboration and the Future of Advanced Therapies

Lilly’s Foundayo Nod Launches New Battle With Novo, M&A Mania Continues, Tariffs Hit Pharma

The Radiotherapeutics Moment: How Isotopes are Changing Cancer Treatment

Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes

The BioSpaces podcast episode centers on recent biopharma M&A activities, highlighting significant deals and their implications. Merck's $6.7 billion acquisition of Terns is examined in light of Merck's upcoming loss of exclusivity for Keytruda. Eli Lilly's strategic diversification into sleep disorder drugs with the a...

Beyond Buzzwords in Longevity Investing

LongeVC's Sergey Jakimov and Artem Trotsyuk discuss pragmatic longevity investing, emphasizing the importance of targeting specific age-related diseases rather than pursuing aging as an abstract concept. They highlight the need for data-backed approaches, measurable endpoints, and adherence to FDA regulatory paths, cau...

Gilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More

Inside the Race to Build the Next Generation of AI Drug Discovery Platforms